OBJECTIVES: To document tumoricidal events after intravenous administration of a vascular targeting agent combretastatin A-4-phosphate (CA4P) in rodent liver tumors by using multiparametric magnetic resonance imaging (MRI) in correlation with microangiography and histopathology. MATERIALS AND METHODS: Thirty rhabdomyosarcomas of 8 to 14 mm in diameter were obtained 16 days after implantation in liver lobes of 15 rats. Using a 1.5T magnet and a 4-channel wrist coil, T2-weighted imaging (T2WI), pre- and postcontrast T1-weighted imaging (T1WI), diffusion-weighted imaging (DWI), and dynamic susceptibility imaging (DSI) with relative blood volume (rBV) and flow (rBF) maps were acquired at baseline, 1 hour, 6 hours, and 48 hours after iv injectio...
AbstractCombretastatin A4 phosphate (CA4P) causes rapid disruption of the tumor vasculature and is c...
International audienceEarly imaging or blood biomarkers of tumor response is needed to customize ant...
International audienceEarly imaging or blood biomarkers of tumor response is needed to customize ant...
AIM: To compare therapeutic responses of a vascular-disrupting-agent, combretastatin-A4-phosphate (C...
To evaluate hepatobiliary-specific contrast agent (CA) mangafodipir trisodium (Mn-DPDP)-enhanced mag...
To better inform the next clinical trials of vascular disrupting agent combretastatin-A4-phosphate (...
Vascular disrupting agents (VDAs) have entered clinical trials for over 15 years. As the leading VDA...
BACKGROUND: Tumours growing in organs of different vascular environment could exhibit diverse respon...
AbstractOBJECTIVE: Differently located tumors of the same origin may exhibit diverse responses to th...
AbstractThe noninvasive assessment of anticancer treatment efficacy is very important for the improv...
Combretastatin A4 phosphate (CA4P) causes rapid disruption of the tumor vasculature and is currently...
AbstractThe noninvasive assessment of anticancer treatment efficacy is very important for the improv...
Combretastatin A4 phosphate (CA4P) causes rapid disruption of the tumor vasculature and is currently...
AbstractCombretastatin A4 phosphate (CA4P) causes rapid disruption of the tumor vasculature and is c...
PURPOSE: To compare dynamic contrast material-enhanced magnetic resonance (MR) imaging and diffusion...
AbstractCombretastatin A4 phosphate (CA4P) causes rapid disruption of the tumor vasculature and is c...
International audienceEarly imaging or blood biomarkers of tumor response is needed to customize ant...
International audienceEarly imaging or blood biomarkers of tumor response is needed to customize ant...
AIM: To compare therapeutic responses of a vascular-disrupting-agent, combretastatin-A4-phosphate (C...
To evaluate hepatobiliary-specific contrast agent (CA) mangafodipir trisodium (Mn-DPDP)-enhanced mag...
To better inform the next clinical trials of vascular disrupting agent combretastatin-A4-phosphate (...
Vascular disrupting agents (VDAs) have entered clinical trials for over 15 years. As the leading VDA...
BACKGROUND: Tumours growing in organs of different vascular environment could exhibit diverse respon...
AbstractOBJECTIVE: Differently located tumors of the same origin may exhibit diverse responses to th...
AbstractThe noninvasive assessment of anticancer treatment efficacy is very important for the improv...
Combretastatin A4 phosphate (CA4P) causes rapid disruption of the tumor vasculature and is currently...
AbstractThe noninvasive assessment of anticancer treatment efficacy is very important for the improv...
Combretastatin A4 phosphate (CA4P) causes rapid disruption of the tumor vasculature and is currently...
AbstractCombretastatin A4 phosphate (CA4P) causes rapid disruption of the tumor vasculature and is c...
PURPOSE: To compare dynamic contrast material-enhanced magnetic resonance (MR) imaging and diffusion...
AbstractCombretastatin A4 phosphate (CA4P) causes rapid disruption of the tumor vasculature and is c...
International audienceEarly imaging or blood biomarkers of tumor response is needed to customize ant...
International audienceEarly imaging or blood biomarkers of tumor response is needed to customize ant...